BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bladder / Urothelial Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Bladder / Urothelial 
 Cancer\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05965856-2044@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05965856)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanc
 ed or Metastatic Urothelial Carcinoma and Other Solid Tumors\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05965856
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405425-2044@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06405425)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metasta
 tic Urothelial Carcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0640
 5425
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06237920-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06237920)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Stage II-II
 Ia Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without R
 elatlimab\nEstimated primary completion: 1 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06237920
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682728-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06682728)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Adjuvant Sa
 cituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma 
 at High-Risk Recurrence\nEstimated primary completion: 1 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06682728
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682728-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06682728)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelia
 l Carcinoma at High-Risk Recurrence\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab
 -govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06682728
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04164082-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04164082)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing
  the Addition of an Anti-cancer Drug\, Pembrolizumab\, to the Usual Intrav
 esical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unres
 ponsive Non-muscle Invasive Bladder Cancer\nEstimated primary completion: 
 9 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04164082
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: A Study
  of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Tha
 t Expresses HER2\nEstimated primary completion: 11 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer
  That Expresses HER2\nEstimated primary completion: 11 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04180371-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2
  Expression\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04180371
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04953104-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04953104)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: ARID1A and/
 or KDM6A Mutation and CXCL13 Expression\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04953104
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528483-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06528483)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle
 -Invasive Bladder Cancer\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 28483
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Avelumab\, phase 3\, Urothelial Carcinoma.\nStudy: Continued Ac
 cess Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab 
 Parent Studies That Are Closing\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined With Toripalimab For First-line Treatment of Uro
 thelial Carcinoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05775471-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05775471)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radica
 l Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05775471
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Probiot
 ics in Advanced Urothelial Carcinoma\nEstimated primary completion: 1 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6904573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Pro
 biotics in Advanced Urothelial Carcinoma\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitam
 ab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06904573
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03244384-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03244384)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Testing
  MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladd
 er Cancer and Locally Advanced Urothelial Cancer\nEstimated primary comple
 tion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03244384
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Disitam
 ab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urot
 helial Cancer Expressing HER2\nEstimated primary completion: 29 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0591129
 5
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2\nEstimated primary completion: 29 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05911295
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Therap
 y and Durvalumab With or Without Tremelimumab in Treating Participants Wit
 h Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstimate
 d primary completion: 31 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406713-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05406713)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab in Muscle-invasive Bladder Cancer\nEstimated primary completion: 31
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05406713
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-2015@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Tremelimumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Ther
 apy and Durvalumab With or Without Tremelimumab in Treating Participants W
 ith Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstima
 ted primary completion: 31 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03744793-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Avelumab: Phase 2 readout est. (NCT03744793)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pemetrexed a
 nd Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial
  Cancer\nEstimated primary completion: 31 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03744793
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591805-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07591805)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: HER
 O-UTUC: Intravesical RC48 After RNU for HER2+ UTUC\nEstimated primary comp
 letion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07591805
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535218-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05535218)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk\, Loca
 lized Bladder Cancer\nEstimated primary completion: February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05535218
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Sacit
 uzumab Govitecan Plus EV in Metastatic UC\nEstimated primary completion: 1
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04724018
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Urothelial Carcinoma.\nStud
 y: Sacituzumab Govitecan Plus EV in Metastatic UC\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04724018
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing the
  Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With 
 One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
 \nEstimated primary completion: 28 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2009@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Ipilimumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing th
 e Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With
  One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumor
 s\nEstimated primary completion: 28 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632951-990@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Budigalimab: Phase 2 readout est. (NCT06632951)
DESCRIPTION:Budigalimab\, phase 2\, Urothelial Carcinoma.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity When Intravenously 
 (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigali
 mab in Adult Participants With Urothelial Carcinoma (UC)\nEstimated primar
 y completion: March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06632951
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06983210-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06983210)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Clinical Tr
 ial of AM80 in Combination With Gemcitabine\, Cisplatin\, and Nivolumab in
  Patients With Urothelial Carcinoma\nEstimated primary completion: 1 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06983210
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04106115-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT04106115)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: DURvalumab in 
 Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder 
 CancEr\nEstimated primary completion: 30 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04106115
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03504163-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03504163)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatme
 nt for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Gr
 ade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03504163
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101096-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05101096)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Sacituzumab Govitecan (SG) in Japanese Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: May 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101
 096
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845814-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05845814)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/
 - Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mU
 C) (MK-3475-04B/KEYMAKER-U04)\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05845814
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639347-2064@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT06639347)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2\, Urothelial Carcinoma.\nStud
 y: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carc
 inoma\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06639347
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239624-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05239624)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin and Pembrolizumab in People With Bladder Cancer\nEstimated pri
 mary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05239624
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857175-2044@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06857175)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in P
 atients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
 \nEstimated primary completion: June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06857175
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332351-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07332351)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadju
 vant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pem
 brolizumab for the Treatment of Muscle Invasive Bladder Cancer\, TRIFECTA 
 Trial\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07332351
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03854474-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03854474)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Testi
 ng the Addition of Tazemetostat to the Immunotherapy Drug\, Pembrolizumab 
 (MK-3475)\, in Advanced Urothelial Carcinoma\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03854474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892860-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Avelumab: Phase 2 readout est. (NCT06892860)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Comparing 3 
 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab i
 n Advanced Urothelial Cancer\nEstimated primary completion: 30 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06892860
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02845323-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02845323)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadjuvant
  Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemothera
 py-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Blad
 der\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02845323
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263153-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06263153)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Futibatinib in C
 ombination With Durvalumab Prior to Cystectomy for the Treatment of Muscle
 -Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based T
 herapy\nEstimated primary completion: 31 July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06263153
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061964-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07061964)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Combini
 ng Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Remo
 val After Treatment Shrinks Muscle Invasive Bladder Cancer\, BRIGHT Trial\
 nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07061964
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720921-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07720921)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Neo
 adjuvant Disitamab Vedotin\, Toripalimab\, and Radiotherapy for High-risk 
 UTUC ( LUXUS07.1 )\nEstimated primary completion: 1 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07720921
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628767-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT04628767)
DESCRIPTION:Durvalumab\, phase 2/3\, Urothelial Carcinoma.\nStudy: Testing 
 the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for P
 atients With High-Grade Upper Urinary Tract Cancer\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04628767
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588179-11071@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:SHR-1501: Phase 1/2 readout est. (NCT06588179)
DESCRIPTION:SHR-1501\, phase 1/2\, Non-Muscle Invasive Bladder Cancer.\nStu
 dy: SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Blad
 der Cancer Which is Not Completely Resectable by TURBt\nEstimated primary 
 completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/shr-1501#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06588179
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1980@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Urothelial Carcinoma.\nStudy
 : Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Age
 nts in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1986@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Rilvegostomig\, phase 2\, Biliary Tract Cancer.\nStudy: Study o
 f Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Pa
 tients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809140-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06809140)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatmen
 t of Muscle-invasive Bladder Cancer\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 09140
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05917158-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT05917158)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment 
 of Upper Tract Urothelial Carcinoma\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05917158
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279597-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07279597)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A P
 hase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder P
 reservation in HER2-Positive Muscle-Invasive Bladder Cancer\nEstimated pri
 mary completion: 10 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07279597
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503614-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06503614)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Trial of Durva
 lumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer\nE
 stimated primary completion: 22 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06503614
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02717156-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02717156)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Multicohort Pha
 se II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02717156
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584733-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07584733)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Bio
 marker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tis
 lelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07584733
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2064@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic U
 rothelial Carcinoma\nEstimated primary completion: 31 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225596-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06225596)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study B
 T8009-230 in Participants With Locally Advanced or Metastatic Urothelial C
 ancer (Duravelo-2)\nEstimated primary completion: March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06225596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225596-2820@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zelenectide pevedotin: Phase 2 readout est. (NCT06225596)
DESCRIPTION:Zelenectide pevedotin\, phase 2\, Urothelial Carcinoma.\nStudy:
  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urot
 helial Cancer (Duravelo-2)\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zelenectide-pevedotin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0622559
 6
URL:https://assetmemo.bio/drug/zelenectide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356155-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06356155)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study o
 f Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urotheli
 al Cancer\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06356155
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183319-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07183319)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Circula
 ting Tumor DNA Response In Urothelial Cancer\nEstimated primary completion
 : March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07183319
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfort
 umab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Ca
 rcinoma (MK-3475-04C/KEYMAKER-U04)\nEstimated primary completion: 31 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648
 3334
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Durvalumab\, phase 2\, Urothelial Carcinoma.\nStudy: Ceralasert
 ib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patie
 nts With Solid Tumors\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03682289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480356-10925@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TARA-002: Phase 3 readout est. (NCT07480356)
DESCRIPTION:TARA-002\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Efficacy and Safety of Intravesical TARA-002 Compared With Investigator'
 s Choice of Intravesical Chemotherapy in Participants With BCG-naïve High
 -grade Non-muscle Invasive Bladder Cancer\nEstimated primary completion: A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07480
 356
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919965-11225@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:TAR-210: Phase 3 readout est. (NCT06919965)
DESCRIPTION:TAR-210\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy:
  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in
  Participants With High Risk Non-Muscle-Invasive Bladder Cancer\nEstimated
  primary completion: 6 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tar-210#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06919965
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06210490-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06210490)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A C
 linical Study of the Efficacy and Safety of Disitamab Vedotin in Combinati
 on With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTU
 C Patients With High Risk Factors for Recurrence After Radical Surgery\nEs
 timated primary completion: 31 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06210490
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05656235-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05656235)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Renal R
 etention in High Grade Upper Tract Urothelial Cancer\nEstimated primary co
 mpletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05656235
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374549-10784@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sutantatug envedotin: Phase 2 readout est. (NCT07374549)
DESCRIPTION:Sutantatug envedotin\, phase 2\, Urothelial Carcinoma.\nStudy: 
 SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma\nEstimate
 d primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sutantatug-envedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07374549
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or 
 Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0497
 7453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2494@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GI-101A: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:GI-101A\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: GI-10
 1/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvat
 inib in Advanced Solid Tumors\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gi-101a#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04977453
URL:https://assetmemo.bio/drug/gi-101a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07717242)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Sun
  Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Blad
 der Cancer\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07717242
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545955-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06545955)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Muscle Invasive Bladder Cancer.\n
 Study: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or 
 in Combination With Chemotherapy or Immunotherapy in Participants With Hig
 h-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer\nEstimated pri
 mary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06545955
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923190-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05923190)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma\nEst
 imated primary completion: 1 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05923190
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03711032-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03711032)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Muscle Invasive Bladder Cancer.\n
 Study: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With 
 Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Ca
 ncer (HR NMIBC) (MK-3475-676/KEYNOTE-676)\nEstimated primary completion: 3
 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03711032
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087860-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07087860)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Therape
 utic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatme
 nt of Bladder Cancers\nEstimated primary completion: 7 August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07087860
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137262-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05137262)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Phase II Multi
 center Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 473
 6) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladde
 r\nEstimated primary completion: 31 August 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05137262
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221942-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07221942)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front
 -Line Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07221942
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869836-2282@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07869836)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-
 based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer 
 After Progression on Anti-PD-(L)1-based Therapy\nEstimated primary complet
 ion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 rastuzumab-brengitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07869836
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immunot
 herapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-Mus
 cle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03317158
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-2015@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Tremelimumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immun
 otherapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-M
 uscle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03317158
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106762-2044@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07106762)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Urothelial Carcinoma.\nSt
 udy: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemothe
 rapy for Metastatic Urothelial Cancer With Disease Progression on or After
  Immunotherapy\nEstimated primary completion: 26 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07106762
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643519-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07643519)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadju
 vant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Canc
 er and Upper Tract Urothelial Carcinoma\nEstimated primary completion: Feb
 ruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07643519
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562830-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05562830)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Sub
 study of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/
 L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (
 MK-3475-04A)\nEstimated primary completion: 26 February 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05562830
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05318573-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05318573)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate Safety\, Efficacy of FF-10832 in Combo With Pembrolizum
 ab in Urothelial & Non-small Cell Lung Cancer\nEstimated primary completio
 n: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05318573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498907-2454@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07498907)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing
  Cisplatin-Ineligible Upper Tract Urothelial Carcinoma\nEstimated primary 
 completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07498907
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129993-1980@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Datopotamab Deruxtecan: Phase 2/3 readout est. (NCT07129993)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2/3\, Urothelial Carcinoma.\nStu
 dy: Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus G
 emcitabine Plus Carboplatin or Cisplatin in Participants With Locally Adva
 nced or Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab
 -deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07129993
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07526792-10784@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07526792)
DESCRIPTION:Sutantatug envedotin\, phase 3\, Urothelial Carcinoma.\nStudy: 
 SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Ur
 othelial Carcinoma\nEstimated primary completion: 1 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07526792
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092958-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Avelumab: Phase 3 readout est. (NCT05092958)
DESCRIPTION:Avelumab\, phase 3\, Urothelial Carcinoma.\nStudy: Testing the 
 Addition of the Anti-cancer Drug\, Cabozantinib\, to the Usual Immunothera
 py Treatment\, Avelumab\, in Patients With Metastatic Urothelial Cancer\, 
 MAIN-CAV Study\nEstimated primary completion: 15 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05092958
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667335-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07667335)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Enfor
 tumab Vedotin\, Pembrolizumab and Quemliclustat for the Treatment of Unres
 ectable Locally Advanced and Metastatic Urothelial Cancer\nEstimated prima
 ry completion: 16 July 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07667335
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Avelumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: QUILT-3.055
 : A Study of Combination Immunotherapies in Patients Who Have Previously R
 eceived Treatment With Immune Checkpoint Inhibitors\nEstimated primary com
 pletion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03228667
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06493552-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06493552)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Solid Tumors.\nStudy: Modular Trial
  of sEphB4-HSA in EphrinB2-High Solid Tumors\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06493552
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04
  (TP04)]\nEstimated primary completion: 30 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1980@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-P
 anTumor04 (TP04)]\nEstimated primary completion: 30 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908979-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07908979)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Risk-En
 abled Therapy After Initiating EV/Pembro for Bladder Cancer\nEstimated pri
 mary completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07908979
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726992-11071@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:SHR-1501: Phase 3 readout est. (NCT07726992)
DESCRIPTION:SHR-1501\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BC
 G in Subjects With Papillary-Only NMIBC\nEstimated primary completion: Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1501#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772
 6992
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiothe
 rapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstima
 ted primary completion: 31 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study o
 f Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot
  Be Removed or Has Spread\nEstimated primary completion: April 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03547973
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Study of Sacituzumab Govitecan in Participants With Urothelial Cancer Tha
 t Cannot Be Removed or Has Spread\nEstimated primary completion: April 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03547973
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-2017@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Avelumab: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Avelumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study of Sac
 ituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be R
 emoved or Has Spread\nEstimated primary completion: April 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03547973
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987241-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT05987241)
DESCRIPTION:Nivolumab\, phase 2/3\, Urothelial Carcinoma.\nStudy: Testing t
 he Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use
  of Immunotherapy After Surgical Removal of the Bladder\, Kidney\, Ureter\
 , and Urethra for Urothelial Cancer Treatment\, MODERN Study\nEstimated pr
 imary completion: 2 September 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05987241
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1980@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Urothelial Carcinoma.\nStudy
 : An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd +
  Rilvegostomig vs SoC in Adult Participants With High-risk MIUC\nEstimated
  primary completion: 11 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1986@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Rilvegostomig\, phase 3\, Urothelial Carcinoma.\nStudy: An Open
 -label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegos
 tomig vs SoC in Adult Participants With High-risk MIUC\nEstimated primary 
 completion: 11 September 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524544-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06524544)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: A Study
  Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy
  Versus Standard of Care in the Treatment of Advanced Urothelial Cancer\nE
 stimated primary completion: 31 December 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06524544
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524544-1992@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06524544)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govite
 can-hziy Versus Standard of Care in the Treatment of Advanced Urothelial C
 ancer\nEstimated primary completion: 31 December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06524544
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: KEYMA
 KER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfort
 umab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-0
 4D/KEYMAKER-U04)\nEstimated primary completion: 8 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951179-10925@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:TARA-002: Phase 2 readout est. (NCT05951179)
DESCRIPTION:TARA-002\, phase 2\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Ad
 ults With High-grade Non-muscle Invasive Bladder Cancer\nEstimated primary
  completion: October 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tara-002#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05951179
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770582-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06770582)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing
  the Addition of the Immunotherapy Drug\, Pembrolizumab\, to Radiation The
 rapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy
  for Bladder Cancer\, PARRC Trial\nEstimated primary completion: 1 Februar
 y 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 70582
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1974@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimated p
 rimary completion: 30 April 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822373-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07822373)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: A Phase
  2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pemb
 rolizumab in Patients With Muscle-Invasive Urothelial Cancer\nEstimated pr
 imary completion: November 2034. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07822373
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
